BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS BRINGS DIGITAL MENTAL HEALTH TECHNOLOGY TO PSYCHEDELICS CLINICAL TRIALS
Could microdosing + this new technology reduce pain in cancer patients?
MindBio Therapeutics is developing a technology platform to integrate with psychedelic therapy to prevent the mental health of cancer patients from deteriorating.
By utilizing wearable devices, the platform is designed to help with pain management to prevent depression, existential distress and anxiety.
MindBio Therapeutics will use the mindfulness app in an upcoming Phase 2 microdosing trial, which is funded by the New Zealand government, to see if it provides additional benefits to late-stage cancer patients compared to microdosing alone.
The company aims to commercialize the application globally and believes the tech has potential to receive government funding in Europe.